TURFAN, China, April 24, 2025 /PRNewswire/ — It has been observed that employees from the power supply company have proactively constructed “love nests” in designated safe areas, effectively protecting both the birds and the power grid. On April 24th, Maifeisha Aihemaiti, a third-grade student participating in the “Guarding the Fluttering Migratory Birds” initiative at the Aiding Lake National Wetland Park, expressed her delight. 

During the “Bird Loving Week,” State Grid Turfan Power Supply Company actively implemented the public welfare brand practice activity titled “Guarding the Fluttering Migratory Birds” within the Aiding Lake region and its surrounding areas. This event integrates power safety with ecological protection through various means such as scientific education, interactive practices, and the creation of “love bird nests,” thereby infusing “power grid” strength into enhancing ecological and environmental conservation efforts. 

Currently, it is the migratory season for birds. To strengthen the protection of bird habitats, the company has established a “Line Protection and Bird Love Team” to conduct specialized patrols along the routes surrounding the Aiding Lake Wetland. These patrols monitor the operational status of the lines and safeguard the migratory flight paths of birds. Additionally, staff members have developed bird-friendly devices, installed “love nests” on specific poles and towers, guided birds to remain within safe zones, and promoted the harmonious coexistence of power grid safety and the ecological environment in the region. 

Since the launch of the “Protecting Lines and Loving Birds” campaign, the company has invited over 100 tourists and staff members from the Aiding Lake Wetland to participate in bird protection activities. They have disseminated knowledge regarding power facilities and bird protection, distributed promotional materials, and ensured the safety of more than 10 bird nests, significantly enhancing public awareness and participation. This fosters a positive social atmosphere conducive to promoting the ecological protection of the Aiding Lake Wetland. 

Moving forward, State Grid Turfan Power Supply Company will continue to embrace the concept of green development, earnestly implement various bird protection volunteer activities, integrate biodiversity conservation into the entire process of power grid construction, and write a new chapter in the harmonious coexistence between humans and nature. 

– Compact, High-heat-dissipation Design Sets New Standard for OBC –

KYOTO, Japan, April 24, 2025 /PRNewswire/ — ROHM Co., Ltd. has developed new 4-in-1 and 6-in-1 SiC molded modules in the HSDIP20 package for power-factor-correction (PFC) circuits and LLC-resonant converters (LLC) used in the onboard charger (OBC) for electric vehicles (xEVs). The lineup includes six models rated at 750V (BSTxxx1P4K01) and seven at 1200V (BSTxxx2P4K01), integrating essential power conversion circuits into a compact module that reduces design workload and supports the miniaturization of the OBC.

Figures: Product features
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202504177553/_prw_PI1fl_W6M5NDFu.jpg 

With the rapid electrification of automobiles driving decarbonization efforts worldwide, xEVs are moving to higher battery voltages to extend driving range and speed up charging. Consequently, demand is rising for higher-output OBCs and still-compact and lightweight DC-DC converters. Achieving higher power density requires advanced heat dissipation, but discrete-based designs often struggle with thermal management. ROHM’s HSDIP20 effectively resolves these issues, enabling greater power output while contributing to smaller electric powertrains.

Equipped with an insulating substrate that delivers excellent heat dissipation, the HSDIP20 suppresses chip temperature rise even under high-power conditions. In a typical PFC circuit for OBC applications, a top-side cooled discrete configuration using six devices was compared with a single HSDIP20 6-in-1 module under identical conditions. During 25W operation, the HSDIP20 operated approximately 38 degrees C cooler than the discrete setup. This superior thermal performance supports higher current in a compact form factor, achieving power density more than three times that of top-side cooled discretes and 1.4 times that of similar DIP modules. In the same PFC circuit, the HSDIP20 package reduces mounting area by approximately 52%, significantly contributing to the miniaturization of the OBC and other power conversion systems.

Figures: Performance of HSDIP20 in PFC circuits
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202504177553/_prw_PI2fl_5vR3E310.jpg 

Going forward, ROHM will continue to develop SiC modules that combine compactness and high efficiency, including automotive SiC IPMs designed for greater reliability in smaller packages. To facilitate quicker adoption of HSDIP20 products, ROHM provides robust application-level support, including in-house motor testing equipment, simulations and thermal design data. Two evaluation kits, one for double-pulse testing and another for three-phase full-bridge implementations, are also available, enabling near real-world performance assessments.

Figures: Product lineup
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202504177553/_prw_PI3fl_1fO5AMI4.jpg 

Release: https://www.rohm.com/news-detail?news-title=2025-04-24_news_hsdip&defaultGroupId=false 

About ROHM: https://kyodonewsprwire.jp/attach/202504177553-O1-5j62ZTQ4.pdf 

Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202504177553/_prw_PI4fl_7uQ1147X.jpg 

Official website: https://www.rohm.com/ 

CHENGDU, China, April 24, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30 to June 3. Results include data from its TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be published on the ASCO’s official website on May 22, 2025, local time.

Detailed information on the studies selected for ASCO 2025 are as follows:

Title: Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
Presentation Type: Oral
Abstract Number: 8507
Session Date and Time: 6/1/2025 8:00 AM-11:00 AM CDT

Title: Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
Presentation Type: Oral
Abstract Number: 6004
Session Date and Time: 5/31/2025 1:15 PM-4:15 PM CDT

Title: Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC): Initial results from the Phase II OptiTROP-Breast05 study.
Presentation Type: Rapid oral
Abstract Number: 1019
Session Date and Time: 5/30/2025 2:45 PM-4:15 PM CDT

Title: Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.
Presentation Type: Poster
Abstract Number: 8529
Session Date and Time: 5/31/2025 1:30 PM-4:30 PM CDT

Title: Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study.
Presentation Type: Poster
Abstract Number: 8615
Session Date and Time: 5/31/2025 1:30 PM-4:30 PM CDT

Title: Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer.
Presentation Type: Poster
Abstract Number: 6098
Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT

About Sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as Non-small Cell Lung Cancer (NSCLC), breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).

To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world’s first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, the NDA application for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy was accepted by the National Medical Products Administration (NMPA), and was included in the priority review and approval process. As of today, Kelun-Biotech has initiated 8 registrational clinical studies in China. MSD has initiated 12 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD.

About Tagitanlimab

Tagitanlimab is the first PD-L1 monoclonal antibody (mAb) globally to receive authorization for the first-line treatment of NPC. Previously, the National Medical Products Administration (NMPA) has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively.

About KL590586 (A400/EP0031)

A400, a novel next-generation selective RET inhibitor for NSCLC, MTC and other solid tumors with a high prevalence of RET alterations. We are currently conducting pivotal clinical study for both 1L and 2L+ advanced RET+ NSCLC as well as a phase 1b/2 clinical study for RET+ MTC and solid tumor in China.

In March 2021, we granted Ellipses Pharma, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries under the code EP0031.

In March 2024, it was announced that EP0031/A400 was granted Fast Track designation by the FDA for the treatment of RET-fusion positive NSCLC. In April 2024, EP0031/A400 was cleared by the FDA to progress into Phase 2 clinical development and is now open in the US, UK, EU and UAE.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

GUANGZHOU, China, April 24, 2025 /PRNewswire/ — At its 137th session, China Import and Export Fair (Canton Fair) continues to demonstrate its capacity to respond swiftly to evolving global consumer trends. With its broad product range and competent pool of suppliers, the Fair offers overseas buyers an efficient, one-stop platform to source tailored solutions for emerging lifestyle demands, such as the growing glamping economy in North America and Europe.

Glamping, short for “glamorous camping,” caters to younger generations who value outdoor escapes without compromising comfort. This market is evolving beyond tents and sleeping bags to a large, fancy tent with additional items that blend luxury with nature. Whether for portable appliances or smart outdoor gear, the Canton Fair connects trend-driven buyers with suppliers ready to deliver quality, innovation, and scale.

Guangdong ICECO Enterprise Co., Ltd., a manufacturer that offers a range of camping accessories, including cooler boxes and mobile fridges, believes that its new series of portable fridges and freezers is an ideal option for glamping. “These metal classics freezers reflect both durability and refined aesthetics,” said Rain Xie, Director of the Product Department at ICECO. With dual-zone functionality for cooling and freezing, the products meet the complex needs of today’s outdoor lifestyles. As a long-time participant of Canton Fair, ICECO has leveraged the Fair to expand its global footprint and looks forward to further engagement during Phase 3, which will feature a sports and tourism leisure products zone and present more solutions for glamping business owners.

Zhejiang Sorbo Technology Co., Ltd., known for its diverse portfolio of outdoor electronics, including mosquito-killer lamps and multi-functional camping lights, provides essence elements that help create a peaceful and cozy glamping atmosphere. One of its patented products, a rechargeable fly fan with lamp repellent, speaks directly to the comfort and convenience expectations of glamping enthusiasts who might bothered by mosquitoes and flies outdoors. Its multi-functional repellent camping lantern combines a camping light, mosquito repellent, and charger into a single, easy-to-carry device, making it ideal for late-night campfire chats or early-morning trail preparations. 

Renowned as one of the world’s largest trade fairs, the Canton Fair stands out for its vast exhibit range and the strong manufacturing and customization capabilities of its exhibitor, empowering global buyers to source various products for trend-aligned solutions like those needed in the glamping boom.